<DOC>
	<DOCNO>NCT00591383</DOCNO>
	<brief_summary>Single arm , open label , Phase I , dose-escalation study indibulin combination erlotinib subject advance histologically confirm , solid tumor standard therapy exist treatment erlotinib consider medically acceptable .</brief_summary>
	<brief_title>Phase I Study Indibulin Combination With Erlotinib Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Subjects advance , histologically confirm solid tumor standard therapy exist treatment erlotinib consider medically acceptable . 2 . ≥18 year age 3 . ECOG performance score ≤2 4 . Eligible subject MUST least one measurable lesion define RECIST guideline . Measurable lesion MUST NOT previously irradiate field injected biological agent . 5 . Lifeexpectancy ≥12 week 6 . No 2 prior chemotherapy regimens metastatic disease 7 . Adequate bone marrow , liver renal function assess follow laboratory requirement conduct &lt; 2 week prior Study Day 1 : Creatinine ≤1.5×upper limit normal ( ULN ) OR calculate creatinine clearance ≥50 cc/min Total bilirubin ≤1.5×ULN Alanine transaminase ( ALT ) aspartate transaminase ( AST ) ≤2.5×ULN White blood cell count ≥3.0×109/L Absolute Neutrophil Count ( ANC ) ≥1.5×109/L Platelets ≥100×109/L Hemoglobin ≥10 g/dL 8 . Written inform consent compliance ZIOPHARM policy Human Investigation Review Committee jurisdiction site . 9 . Each man woman childbearing potential must agree use reliable method contraception study 3 month follow last dose study drug . 1 . New York Heart Association ( NYHA ) functional class ≥3 myocardial infarction within 6 month ( see Appendix 5 ) 2 . Uncontrolled cardiac arrhythmia asymptomatic atrial fibrillation 3 . Subjects receive cytochrome P450inducing anticonvulsant ( EIAEDs : eg , phenytoin , carbamazepine , phenobarbital , primidone , oxcarbezine ) 4 . Subjects may take CYP3A4 inducer ( rifampicin ) 5 . Subjects must evidence bleed diathesis coagulopathy 6 . Subjects international normalize ration ( INR ) &gt; 1.5 exclude , unless subject full dose warfarin 7 . Subjects fulldose anticoagulant ( eg , warfarin ) eligible provide follow criterion meet : The subject inrange INR ( usually 2 3 ) stable dose oral anticoagulant stable dose low molecular weight heparin The subject active bleeding pathological condition carry high risk bleeding ( eg , tumor involve major vessel know varix . 8 . Subjects prophylactic anticoagulation ( ie , lowdose warfarin ) eligible provide coagulation parameter level follow : prothrombin time ( INR prothrombin time ) &lt; 1.1×institutional ULN 9 . Pregnancy and/or lactation 10 . Uncontrolled systemic infection ( documented microbiological study ) 11 . Anticancer chemotherapy immunotherapy study within 4 week study entry . Mitomycin C nitrosureas give within 6 week study entry . 12 . Prior treatment EGFR inhibitor 13 . Radiotherapy study within 3 week study entry 14 . Surgery within 4 week start study drug exclude tumor biopsy pharmacodynamic parameter 15 . Investigational drug therapy outside trial within 4 week study entry 16 . History invasive second primary malignancy diagnose within previous 3 year except Stage I endometrial/cervical carcinoma prostate carcinoma treat surgically , nonmelanoma skin cancer 17 . Substance abuse , medical , psychological social condition may interfere subject 's participation study evaluation study result 18 . Any condition unstable could jeopardize safety subject his/her compliance study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Indibulin</keyword>
	<keyword>Erlotinib</keyword>
</DOC>